focus -WSS

focus

author：hotspot 2025-09-27 23:53:25 - browse：55

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

WSS

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Why CTE doesn’t keep Americans from enjoying the Super Bowl

House looks to weaken Medicare negotiation

How to fix the rural physician shortage in the U.S.

Pfizer highlights cancer drugs it thinks could reignite investor interest

A single Democrat is willing to weaken Medicare negotiation power

knowledge

focus

focus

Wildfire smoke exposes gaps in outdoor worker protections

ALS groups 'won't be played again' by the FDA, drug sponsors

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Congress gives doctors Medicare pay bump

United colonoscopy coverage change 'may cost lives,' doctors say

AI gets buy

United colonoscopy coverage change 'may cost lives,' doctors say

Pfizer highlights cancer drugs it thinks could reignite investor interest

The high cost of giving birth even with insurance

Clinical trials giant ICON acquires HumanFirst

focus

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Medical device lobby: We're tired of waiting on Medicare coverage

How to address the problem of discarded donor organs

A protest over insulin prices is seen as a fight for life

Texas Medical Board asked to define abortion emergency exception

Global cancer cases to surge 77% by 2050, WHO report says

explore

hotspot

hotspot

explore